Concert Pharmaceuticals, Inc. CNCE

Institutional shares held 0

0 calls

0 puts

Total value of holdings $0

$0 calls

$0 puts

Market Cap N/A

Institutional ownership N/A

# of Institutions 1

We take great care to ensure that the data presented and summarized in this overview for CONCERT PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.

Quarterly Institutional Activity in CNCE

Shares Bought

Shares Sold

View Transactions

Top Institutions Holding CNCE

View all

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View all

Latest Institutional Activity in CNCE

Top Purchases

Q4 2024

Concourse Financial Group Securities, Inc. Shares Held: 0 ($0)

0 Shares purchased

New Holding

Q4 2022

Kynam Capital Management, LP Shares Held: 4.42M ($0)

2.75M Shares purchased

164.21% Added

Q4 2022

Tang Capital Management LLC Shares Held: 1.15M ($0)

1.15M Shares purchased

New Holding

Q4 2022

Bank Of Montreal Shares Held: 543K ($0)

543K Shares purchased

New Holding

Q4 2022

Black Rock Inc. Shares Held: 1.24M ($0)

411K Shares purchased

49.72% Added

View All Buyers

Top Sells

Q1 2023

Point72 Asset Management, L.P. Shares Held: 0 ($0)

1.34M Shares sold

Closed

Q1 2023

State Street Corp Shares Held: 0 ($0)

141K Shares sold

Closed

Q1 2023

Bit Capital Gmb H Shares Held: 0 ($0)

39K Shares sold

Closed

Q4 2022

Morgan Stanley Shares Held: 591K ($0)

378K Shares sold

39.0% Reduced

Q4 2022

Two Sigma Investments, LP Shares Held: 121K ($0)

247K Shares sold

67.22% Reduced

View All Sellers

About CNCE

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Insider Transactions at CNCE

Insider Transaction List

View all

Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Mar 06 2023	Wilfred E Jaeger Director	SELL Sale (or disposition) back to the issuer	Direct	16,400 -100.0%	-
Mar 06 2023	Wilfred E Jaeger Director	SELL Disposition due to a tender of shares in a change of control transaction	Direct	5,125 -100.0%	-
Mar 06 2023	Jeffrey A Munsie Chief Legal Officer	SELL Sale (or disposition) back to the issuer	Direct	49,699 -100.0%	-
Mar 06 2023	Jeffrey A Munsie Chief Legal Officer	SELL Disposition due to a tender of shares in a change of control transaction	Direct	38,350 -100.0%	-
Mar 06 2023	Nancy Stuart Chief Operating Officer	SELL Sale (or disposition) back to the issuer	Direct	73,233 -100.0%	-
Mar 06 2023	Nancy Stuart Chief Operating Officer	SELL Disposition due to a tender of shares in a change of control transaction	Direct	167,963 -100.0%	-
Mar 06 2023	Roger D Tung Chief Executive Officer	SELL Disposition due to a tender of shares in a change of control transaction	Indirect	147,536 -100.0%	-
Mar 06 2023	Roger D Tung Chief Executive Officer	SELL Sale (or disposition) back to the issuer	Direct	57,916 -100.0%	-
Mar 06 2023	Roger D Tung Chief Executive Officer	SELL Disposition due to a tender of shares in a change of control transaction	Direct	756,427 -100.0%	-
Mar 06 2023	Christi Van Heek Director	SELL Sale (or disposition) back to the issuer	Direct	16,400 -100.0%	-
Mar 06 2023	Christi Van Heek Director	SELL Disposition due to a tender of shares in a change of control transaction	Direct	25,651 -100.0%	-
Mar 06 2023	Thomas G Auchincloss Director	SELL Sale (or disposition) back to the issuer	Direct	16,400 -100.0%	-
Mar 06 2023	Thomas G Auchincloss Director	SELL Disposition due to a tender of shares in a change of control transaction	Direct	17,625 -100.0%	-
Mar 06 2023	Marc A. Becker Chief Financial Officer	SELL Sale (or disposition) back to the issuer	Direct	49,699 -100.0%	-
Mar 06 2023	Marc A. Becker Chief Financial Officer	SELL Disposition due to a tender of shares in a change of control transaction	Direct	56,264 -100.0%	-
Mar 06 2023	James V Cassella Chief Development Officer	SELL Sale (or disposition) back to the issuer	Direct	57,766 -100.0%	-
Mar 06 2023	James V Cassella Chief Development Officer	SELL Disposition due to a tender of shares in a change of control transaction	Direct	80,595 -100.0%	-
Mar 06 2023	Jesper Hoeiland Director	SELL Sale (or disposition) back to the issuer	Direct	16,400 -100.0%	-
Mar 06 2023	Jesper Hoeiland Director	SELL Disposition due to a tender of shares in a change of control transaction	Direct	5,125 -100.0%	-
Mar 06 2023	Peter Barton Hutt Director	SELL Sale (or disposition) back to the issuer	Direct	16,400 -100.0%	-

View All Transactions

Last 12 Months Summary

Buy / Acquisition

0 Shares

From 0 Insiders

Sell / Disposition

0 Shares

From 0 Insiders

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CNCE shares.

Notify only if

Value

Any

Insider Trading

Get notified when an Concert Pharmaceuticals, Inc. insider buys or sells CNCE shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

News

Receive news related to CONCERT PHARMACEUTICALS, INC.

Track Activities on CNCE

Account

Concert Pharmaceuticals, Inc. CNCE

Quarterly Institutional Activity in CNCE

Top Institutions Holding CNCE

Latest Institutional Activity in CNCE

Top Purchases

Top Sells

About CNCE

Insider Transactions at CNCE

Insider Transaction List

Last 12 Months Summary

Track Institutional and Insider Activities on CNCE

Institutional Portfolio Updates

Insider Trading

News